1IC
SNOA icon

1919 Investment Counsel’s Sonoma Pharmaceuticals SNOA Stock Holding History

1919 Investment Counsel’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1
Closed -$5K – 1015
2013
Q4 		$5K Buy
+1
New +$2.66K ﹤0.01% 920

Other funds holding SNOA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

1919 Investment Counsel's SNOA Position: Q1 2014 in Review

1919 Investment Counsel sold out of Sonoma Pharmaceuticals (SNOA) in Q1 2014, closing a stake of 1 share — an estimated $5K sold.

1919 Investment Counsel first reported a position in SNOA in Q4 2013 and held it in 1 quarter. The position peaked at $5K in Q4 2013. 18 funds tracked by Wall St. Rank hold SNOA as of Q1 2014.

  • 1919 Investment Counsel reported no remaining Sonoma Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • 1919 Investment Counsel sold 1 Sonoma Pharmaceuticals share in Q1 2014, an estimated $5K.
  • 1919 Investment Counsel first reported a position in Sonoma Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • 1919 Investment Counsel's Sonoma Pharmaceuticals position peaked at $5K in Q4 2013.
  • 18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2014.

Based on 1919 Investment Counsel's 13F filing for Q1 2014, filed 15 May 2014.